Hospital
Chester County Hospital
Chester County Hospital was paid $10.25M by Medicaid between Aug 2019 and Dec 2024, across 186 billing codes. Its largest line is 99285, emergency room visit (most serious) — 29% of everything it billed.
33Billing provider infoCHESTER COUNTY HOSPITAL
WEST CHESTER, PA 19380
WEST CHESTER, PA 19380
33aNPI1356333579assigned 08/16/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.25M
24GClaims287,433
24DCodes billed186
24AFirst – last monthAug 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#32 of 154
Median peer was paid$2.82M
This provider vs. median3.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 1,000 | $17K | |
| 2020 | 22,982 | $575K | |
| 2021 | 82,519 | $3.66M | |
| 2022 | 66,826 | $2.21M | |
| 2023 | 59,675 | $2.06M | |
| 2024incomplete | 54,431 | $1.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 29% | 11,466 | 10,937 | $3.01M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 12,035 | 11,362 | $1.90M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 6,942 | 6,638 | $1.20M |
| G0378 | Hospital observation service, per hour | 6.9% | 696 | 673 | $711K |
| 36415 | Collection of venous blood by venipuncture | 2.0% | 19,522 | 16,887 | $209K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 1.3% | 3,102 | 2,287 | $136K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 1,930 | 1,782 | $127K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 606 | 589 | $124K |
| 83735 | 1.1% | 15,089 | 13,879 | $118K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.1% | 1,072 | 1,055 | $116K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 19,917 | 17,267 | $111K |
| 83615 | 1.0% | 14,821 | 13,792 | $106K |
174 more codes
| 84460 | 1.0% | 14,634 | $105K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 297 | $101K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,599 | $86K |
| 84550 | <1% | 14,673 | $85K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 86 | $78K |
| 84450 | <1% | 14,238 | $75K | |
| 82247 | <1% | 14,282 | $74K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 720 | $74K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,365 | $72K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,568 | $69K |
| 84075 | <1% | 14,224 | $66K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,960 | $65K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,197 | $64K |
| 59025 | Fetal non-stress test | <1% | 2,115 | $56K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,270 | $54K |
| 84155 | <1% | 14,225 | $54K | |
| 84100 | <1% | 9,387 | $52K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,100 | $50K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 410 | $48K |
| 87581 | <1% | 296 | $48K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 501 | $46K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 170 | $44K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 341 | $43K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 114 | $33K |
| 80053 | Comprehensive metabolic panel | <1% | 2,540 | $31K |
| X0621 | <1% | 150 | $30K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 880 | $27K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 86 | $26K |
| 76830 | Ultrasound, transvaginal | <1% | 419 | $26K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 970 | $25K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 371 | $25K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 300 | $23K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 361 | $23K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 504 | $22K |
| 84484 | <1% | 1,768 | $22K | |
| 76818 | <1% | 236 | $21K | |
| 76801 | <1% | 378 | $21K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 458 | $20K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 233 | $20K |
| 84703 | <1% | 1,875 | $19K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 538 | $16K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 662 | $15K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 497 | $15K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 115 | $14K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 304 | $14K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,060 | $14K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 964 | $14K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 365 | $13K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 722 | $13K |
| 76642 | <1% | 301 | $12K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 584 | $12K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 368 | $12K |
| 87486 | <1% | 299 | $12K | |
| 83880 | <1% | 305 | $12K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 98 | $11K |
| 80320 | <1% | 652 | $10K | |
| 77066 | Tomosynthesis, mammo | <1% | 110 | $10K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 195 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 278 | $8K |
| 93971 | <1% | 103 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 689 | $8K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 278 | $8K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 292 | $8K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 460 | $7K |
| 97162 | <1% | 80 | $7K | |
| 86900 | <1% | 591 | $6K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 43 | $6K |
| 83690 | <1% | 1,046 | $6K | |
| 80061 | Lipid panel | <1% | 367 | $6K |
| 97010 | <1% | 395 | $6K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 42 | $6K |
| 87040 | <1% | 136 | $6K | |
| 36591 | <1% | 106 | $5K | |
| 85027 | <1% | 547 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 532 | $5K |
| 81001 | <1% | 1,373 | $5K | |
| 86850 | <1% | 433 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 241 | $4K |
| 84702 | <1% | 271 | $4K | |
| 76536 | <1% | 73 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 387 | $4K |
| 82962 | <1% | 440 | $4K | |
| 96367 | <1% | 164 | $3K | |
| 73630 | <1% | 206 | $3K | |
| 85610 | <1% | 640 | $3K | |
| 82728 | <1% | 257 | $3K | |
| 72110 | <1% | 114 | $3K | |
| 76770 | <1% | 71 | $3K | |
| 71250 | <1% | 54 | $3K | |
| 76813 | <1% | 52 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 57 | $3K |
| 85730 | <1% | 404 | $3K | |
| 87631 | <1% | 18 | $2K | |
| 82607 | <1% | 177 | $2K | |
| 87653 | <1% | 52 | $2K | |
| 74018 | <1% | 94 | $2K | |
| 77062 | <1% | 91 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 45 | $2K |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 151 | $2K |
| 86901 | <1% | 452 | $2K | |
| 72100 | <1% | 112 | $2K | |
| 83540 | <1% | 212 | $2K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 70 | $2K |
| 94664 | <1% | 77 | $2K | |
| 81003 | <1% | 470 | $2K | |
| 73030 | <1% | 80 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,096 | $2K |
| 84439 | <1% | 120 | $2K | |
| 96417 | <1% | 19 | $2K | |
| 73610 | <1% | 74 | $2K | |
| 86140 | <1% | 180 | $1K | |
| 87070 | <1% | 122 | $1K | |
| 77080 | <1% | 27 | $1K | |
| 81025 | <1% | 172 | $1K | |
| 93970 | <1% | 13 | $1K | |
| 73564 | <1% | 59 | $1K | |
| 85379 | <1% | 69 | $1K | |
| 76820 | <1% | 15 | $1K | |
| 87077 | <1% | 81 | $896.11 | |
| 77065 | Tomosynthesis, mammo | <1% | 13 | $868.83 |
| 73562 | <1% | 51 | $830.95 | |
| 83550 | <1% | 163 | $829.52 | |
| 87480 | <1% | 39 | $824.45 | |
| 87660 | <1% | 39 | $816.24 | |
| 73130 | <1% | 48 | $719.82 | |
| 82550 | <1% | 45 | $690.86 | |
| 85652 | <1% | 125 | $683.16 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,449 | $611.52 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,329 | $587.18 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 875 | $500.64 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 469 | $465.66 |
| 72050 | <1% | 13 | $440.31 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,188 | $388.46 |
| 72070 | <1% | 14 | $372.45 | |
| J3490 | Unclassified drugs | <1% | 583 | $371.80 |
| 87186 | <1% | 42 | $360.48 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 41 | $359.76 |
| 82950 | <1% | 41 | $358.03 | |
| 82570 | <1% | 29 | $313.36 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,285 | $294.96 |
| 96376 | <1% | 14 | $277.76 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 27 | $268.24 |
| 83605 | <1% | 27 | $265.60 | |
| 77061 | <1% | 12 | $260.15 | |
| 73110 | <1% | 17 | $246.29 | |
| 84156 | <1% | 29 | $239.97 | |
| 83020 | <1% | 12 | $214.54 | |
| 87510 | <1% | 12 | $205.58 | |
| 97161 | <1% | 14 | $170.48 | |
| 82746 | <1% | 16 | $141.12 | |
| 80055 | <1% | 13 | $140.16 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,111 | $131.78 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 698 | $123.48 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,397 | $100.70 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 632 | $90.68 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 355 | $52.05 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 376 | $51.56 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 725 | $15.96 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 151 | $14.72 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 235 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 56 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 50 | $0.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 103 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 20 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 426 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 247 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 147 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 393 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 78 | $0.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 15 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 46 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 30 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 44 | $0.00 |
| S5000 | Prescription drug, generic | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSNYDER, JOSHUA (CFO)